Form 4: Beta Bionics CFO Executes Tax-Related Share Sale

CFO Stephen Feider sold 6,676 shares of Beta Bionics to satisfy tax withholding obligations related to RSU vesting.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc., sold 6,676 shares of common stock.
• The transaction occurred on June 2, 2026.
• The shares were sold at a weighted average price of $12.6071 per share.
• The sale was conducted to cover tax withholding obligations resulting from the vesting of restricted stock units.
• Following this transaction, the reporting person retains beneficial ownership of 166,053 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The sale was non-discretionary, specifically executed to satisfy tax obligations associated with equity compensation.

Negatives

• Reduction in the reporting person's direct equity stake in the company.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes are standard corporate practice and generally do not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices where equity awards are partially liquidated to cover mandatory tax liabilities.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was for tax compliance purposes.

Key Dates

Keywords

Beta Bionics, BBNX, Insider Trading, Form 4, CFO, Equity Compensation